Antigenic GM-CSF peptides and antibodies to GM-CSF
US9422367B2 · kind B2 · utility
0Cited by
20References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 26, 2013 |
| Grant date | Aug 23, 2016 |
| Priority date | — |
| Expiry date | Nov 30, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided. The antibodies may be used in therapeutic methods, for example in the treatment of cancer, infectious disease, or autoimmune disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.